Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0W7AB
|
|||
| Drug Name |
Anti-BCMA CAR T cells
|
|||
| Drug Type |
CAR T Cell Therapy
|
|||
| Indication | Multiple myeloma [ICD-11: 2A83; ICD-10: C90.0] | Phase 1 | [1], [2] | |
| Company |
National Cancer Institute (NCI)
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | B-cell maturation protein (TNFRSF17) | Target Info | CAR-T-Cell-Therapy | [1], [2] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT02215967) Study of T Cells Targeting B-Cell Maturation Antigen for Previously Treated Multiple Myeloma | |||
| REF 2 | ClinicalTrials.gov (NCT03602612) T Cells Expressing a Novel Fully-Human Anti-BCMA CAR for Treating Multiple Myeloma | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.